SMAD2 and prostate cancer: MiR-486 is known to drive tumorigenesis by targeting multiple negative regulators of PTEN/PI3K/Akt, FOXO, and TGF-β/Smad2 signaling in cervical cancer and prostate cancer cells [32,33].